logo
NasdaqGS:PRTA logo

Prothena Community

NasdaqGS:PRTA Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

PRTA logo
Prothena
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts

AFFIRM-AL And Alzheimer's Trials Will Unlock New Opportunities

Key Takeaways Successful clinical trials for Birtamimab and Alzheimer's treatments could significantly boost Prothena's revenue through large market opportunities. Strategic partnerships and a strong financial position support pipeline advancement and potential long-term earnings growth.
View narrative
US$51.75
FV
83.6% undervalued intrinsic discount
16.41%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
4 days ago author updated this narrative